37.18
+2.73(+7.92%)
Currency In USD
| Previous Close | 34.45 |
| Open | 34.45 |
| Day High | 38.37 |
| Day Low | 34.02 |
| 52-Week High | 48.26 |
| 52-Week Low | 1.87 |
| Volume | 3.85M |
| Average Volume | 4.12M |
| Market Cap | 3.35B |
| PE | -36.45 |
| EPS | -1.02 |
| Moving Average 50 Days | 32.54 |
| Moving Average 200 Days | 12.1 |
| Change | 2.73 |
If you invested $1000 in Terns Pharmaceuticals, Inc. (TERN) since IPO date, it would be worth $2,021.75 as of January 15, 2026 at a share price of $37.18. Whereas If you bought $1000 worth of Terns Pharmaceuticals, Inc. (TERN) shares 3 years ago, it would be worth $4,177.53 as of January 15, 2026 at a share price of $37.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:05 PM GMT
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of
Terns Announces Pricing of Upsized $650 Million Public Offering
GlobeNewswire Inc.
Dec 10, 2025 4:30 AM GMT
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 s